Skip to main content
ALKS logo

ALKS · Alkermes plc.

Track ALKS — free
$46.85 +1.40 (+3.08%) At close · Nov 18
Market Cap
$7.87B
Shares
168.04M
Volume · Nov 18 1.41M Avg daily vol (3M) 1.89M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$46.85 Open$45.26 Day$45.25–47.06 52W close$27.20–55.22 Avg vol 30d1.8M Short int19.6M · 11.7% of shares · 11.3d Short vol44% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 18
Investor event
About six trial readouts due over the next 12 months

The CEO expects about six trials to read out over the next 12 months. The idiopathic hypersomnia study reads out at the end of the year, and three phase three programs for NT1 and NT2 read out in the middle of the summer. An ADHD phase 2 dose-ranging study follows in the early fall.

3 source passages
And as we move over into the next 12 months from now until the end of next year, we probably have about six trials or so reading out over the course of that time. We have our idiopathic hypersomnia study at the end of the year, three phase three programs, NT1, NT2, reading out in the middle of the summer. That's followed by our ADHD phase 2 dose ranging study in the early fall, and then fatigue in ELX 4510 right after that. Open the document at this passage
Nov 12
Current report 8-K Events of Nov 6
Teva Settles LYBALVI Patent Litigation Under License

Alkermes plc settled Teva’s LYBALVI patent litigation, granting Teva a non-exclusive, royalty-free U.S. license beginning November 12, 2039, or May 12, 2040 if pediatric exclusivity is obtained. The parties filed a Stipulation of Dismissal with Prejudice on November 9, 2026.

Entered into a material agreement
3 source passages
On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of Alkermes plc (the “Company”), entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Teva Pharmaceuticals, Inc. (“Teva”, and together with Alkermes, the “parties”), resolving a patent infringement lawsuit relating to all dosage strengths of the Company’s product LYBALVI® (olanzapine and samidorphan). Pursuant to the Settlement Agreement, Alkermes will grant Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license to make, have made, use, import, sell and offer for sale Teva’s products made under ANDA No. 220379 in the United States beginning on November 12, 2039, or, if Alkermes obtains pediatric exclusivity, on May 12, 2040, or earlier under certain circumstances. On November 9, 2026, the parties filed a joint Stipulation of Dismissal with Prejudice to dismiss the pending legal proceedings. Open the document at this passage
Nov 3
Earnings call
Proprietary sales rise 31%; six orexin studies expected to read out

Alkermes reported proprietary product net sales of $417.3 million, up 31% year-over-year, and expects six orexin studies to read out over the next year.

2 source passages
In the third quarter, net sales from our proprietary product portfolio increased 31% year-over-year to $417.3 million, reflecting the addition of LoomRise and continued demand growth across our established commercial portfolio. Looking ahead, the next year will be a pivotal and data-rich period for Alkermes, with six important studies expected to read out across our orexin portfolio. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
LUMRYZ lifts revenue as Avadel costs drive nine-month loss

Alkermes reported net income of $16.3 million for the three months ended September 30, 2026, but a $49.7 million nine-month net loss as Avadel-related costs rose. LUMRYZ contributed $89.9 million in quarterly product sales, lifting net product sales to $417.3 million.

Revenue $480.13M ▲ 21.8% Net income $16.29M ▼ 80.3% Diluted EPS $0.09 ▼ 81.6%
Read from the MD&A section
5 source passages
Net income was $16.3 million or $0.10 per ordinary share—basic and $0.09 per ordinary share—diluted, for the three months ended September 30, 2026 and net loss was $49.7 million or $0.30 per ordinary share—basic and diluted, for the nine months ended September 30, 2026, compared to net income of $82.8 million and $192.3 million or $0.50 and $1.17 per ordinary share—basic and $0.49 and $1.14 per ordinary share—diluted, for the three and nine months ended September 30, 2025, respectively. The increase in operating expenses was primarily related to the Avadel Acquisition and the increase in interest expense was related to interest incurred on the Facilities. LUMRYZ | 89.9 | — | 89.9 | 226.0 | — | 226.0 Product sales, net | 417.3 | 317.4 | 99.9 | 1,167.1 | 869.2 | 297.9 Litigation or arbitration filed against Alkermes, including securities litigation, or actions (such as citizens petitions) filed against regulatory agencies in respect of our products, may result in financial losses, harm our reputation, divert management resources, negatively impact the approval of our products, or otherwise negatively impact our business. Open the document at this passage
Nov 3
Current report 8-K
Third-quarter revenue reaches $480.1 million

Alkermes plc reported third-quarter revenues of $480.1 million and GAAP net income of $16.3 million for 2026, including LUMRYZ revenue of $89.9 million, and reiterated its 2026 financial expectations.

Financial results
4 source passages
Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2026. — Third Quarter Revenues of $480.1 Million — — GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million — LUMRYZ revenues for the quarter were $89.9 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.75B
Trailing 12 months
Net income (TTM)
−$351,000
Trailing 12 months
Revenue growth YoY
+21.8%
Year over year
Operating margin
3.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$866.42M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.7%
Year over year · more shares
Price change (1Y)
+60.1%
Trailing year
Short interest
11.7%
Latest settlement · 11.3 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 28, 2026
Q2 FY26

TL;DR. Proprietary net sales rose 34% to $411.7 million, with Lybalvi prescriptions up 18%. Full-year GAAP net loss guidance widened to $95 to $115 million from $70 to $90 million, and Lybalvi gross-to-net adjustments are now expected in the high 30s.

Bullish
  • + Proprietary net sales rose 34% year-over-year to $411.7 million.
  • + Lybalvi revenue grew 12% and prescriptions grew 18% year-over-year.
  • + Lybalvi is now covered for more than 80% of insured lives after Part D plan expansion.
  • + No authorized generic of Vivitrol is expected in 2027.
  • + Lumerize IH supplemental NDA submission is planned by year-end.
  • + Orexin agonist long-term extension data show sustained wakefulness gains in NT1 and NT2.
Bearish
  • − Full-year GAAP net loss guidance widened to $95 to $115 million from $70 to $90 million.
  • − Lybalvi gross-to-net adjustments are now expected in the high 30s, with growth to net expanding in the second half.
  • − GAAP net income fell to $0.5 million from $87.1 million, and six-month GAAP net was a $(66.0) million loss versus $109.6 million income a year earlier.
  • − SG&A rose to $217.6 million from $170.8 million year-over-year.
  • − Timing of Vivitrol generic market entry in 2027 remains uncertain.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg +7%
above
RSI (14) 58
neutral
MACD trend Positive
52-week position 70%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +11%
trailing
YTD return +67%
this year
Relative strength +15%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $44 › 200d $41 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +47 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.69% of shares out · ▲ +3.1% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
417 holders — near 3-yr high, broad support
Squeeze score 73
high risk · 0–100
Fundamentals
Strong
Revenue growth −5%
Y/Y
EPS growth −34%
Y/Y
Free cash flow $480.3M
Buyback $172.3M
remaining
Balance sheet $388.6M
net cash
Quant / Vol
risk profile
Moderate
Volatility 39%
annualized · 1-yr
Max drawdown −29%
past year
ATR 3.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the 8-K filed Nov 3, 2026
Year Ending Dec. 31, 2026
Net Tax Benefit Maintained $0
Jul 28, 2026 $0 changed to Nov 3, 2026 $0
FY'26
VIVITROL® net sales Maintained $460M – $480M
Jul 28, 2026 $460M – $480M changed to Nov 3, 2026 $460M – $480M
LYBALVI® net sales Maintained $380M – $400M
Jul 28, 2026 $380M – $400M changed to Nov 3, 2026 $380M – $400M
ARISTADA® net sales Maintained $365M – $385M
Jul 28, 2026 $365M – $385M changed to Nov 3, 2026 $365M – $385M
FY'26 (Feb. 12, 2026 – Dec. 31, 2026)
LUMRYZ® net sales Maintained $315M – $335M
Jul 28, 2026 $315M – $335M changed to Nov 3, 2026 $315M – $335M
Previous outlook earlier release · from the 8-K filed Jul 28, 2026

Still-open targets the latest release did not restate under the same label.

Change in the Fair Value of Contingent Consideration · 2026 $25M
GAAP Net Loss · 2026 $-115M – $-95M
EBITDA · 2026 $75M – $95M
Adjusted EBITDA · 2026 $370M – $410M
Prior guidance period ended · from the Earnings Call filed Jul 28, 2026
Total revenues · third quarter $450M – $470M
R&D expenses · third quarter $120M – $130M
Costs of goods sold · third quarter $85M – $95M
Adjusted EBITDA · third quarter $80M – $100M
SG&A expense · third quarter $215M – $225M
Costs · third quarter $85M – $95M
Guided vs delivered · last 8 settled
Total revenues third quarter
guided $450M – $470M
$480.13M Beat +4.4%
Total revenues full-year 2025
guided $1.43B – $1.49B
$1.48B In line
Total Revenues 2024 Expectations
guided $1.5B – $1.6B
$1.56B In line
Projected Earnings Per Share Year Ending December 31, 2024
guided $2.14
$2.17 Beat +1.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
58 Neutral
MACD trend
Positive Bullish
52-week position
70% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $44 › 200d $41 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +47 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.69% of shares out · ▲ +3.1% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
417 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $27 Now $47 · 70% Range high $55
vs 200-day avg +13% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Long-acting INVEGA products manufacturing and royalty revenues $27.4M Three Months Ended June 30, 2026 filing —
LYBALVI product sales, net $93.9M Three Months Ended June 30, 2026 filing —
Other manufacturing and royalty revenues $26.3M Three Months Ended June 30, 2026 filing —
VUMERITY manufacturing and royalty revenues $30.6M Three Months Ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALKS
Alkermes plc.
this stock
$7.87B +67.4% -5.2% — 11.7%
TAK
Takeda Pharmaceutical Co Ltd
$67.96B +36.4% — — 0.1%
GALDY
Galderma Group AG
$51.90B +7.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.28B +35.3% +4.3% 96.0 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
417
% held
104.2%
Net QoQ
-3.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
163
View
Short & Settlement
Short Interest Rising
Shares short
19.6M
Days to cover
11.3d
Change
+599.4K sh
View
Short Volume
Short vol %
44%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
445
Value
$17.7K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Sep 29, 2026
View
Financials
Financials
Revenue (FY)
$1.5B
Net income (FY)
$241.7M
EPS diluted
$1.43
View
Buybacks
Authorized
$400.0M
Remaining
$172.3M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
31

The CEO expects about six trials to read out over the next 12 months. The idiopathic hypersomnia study reads out at the end of the year, and three phase three programs for NT1 and NT2 read out in the middle of the summer. An ADHD phase 2 dose-ranging study follows in the early fall.

View
Proposed Sales
Value
$94.0K
Shares
2.0K
Filed
Nov 3, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Alkermes Showcases Research From…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
ALKS -2.2% +7.8% +11.1% +3.3% +67.4%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +1.7% +13.3% +14.5% +6.7% +60.4%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$400.00M
Spent (derived)
$227.70M
Remaining
$172.30M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1520262 CUSIP G01767105 13F (30d) 424 filings 387 filers Visit website Investor relations